Le Lézard
Classified in: Business
Subjects: LIC, MAT

Bonify Secures Sales License For Medical Cannabis From Health Canada


Announcement comes on the heels of the appointment of Jeff Peitsch as Executive Chair of the Board and Dalbir Bains as the new President and CEO

WINNIPEG, June 15, 2018 /CNW/ - Winnipeg-based licensed producer Bonify announced that it was granted a sales license by Health Canada under the Access to Cannabis for Medicinal Purpose Regulations (ACMPR). As the only independent cannabis company in Manitoba to receive a sales license, Bonify is now permitted to sell its high quality cannabis directly to patients registered under the ACMPR.

The announcement comes at an opportune time as the industry braces for legalization next month and follows the recent appointment of the company's new President and CEO, Dalbir Bains, who will drive the company's long-term strategic direction working with Bonify's board and shareholders. Bains succeeds Jeff Peitsch who has taken on the role of Executive Chair of the Board.

On news of receiving the sales license, Peitsch said, "We are obviously quite pleased with Health Canada's decision and are thankful to our founding shareholders and key employees who worked diligently with Health Canada and many stakeholders to reach this milestone." 

Bains, who brings extensive retail pharmacy and healthcare experience to the role, as well as a focus on the growing healthcare needs of the population, concurs with Peitsch.

"We couldn't be happier to let registered patients know that they can now buy direct from Bonify, a company that truly puts its customers at the core of everything we do," said Bains. "With the Canadian cannabis industry becoming an increasingly competitive space and with customers' product preferences evolving, delivering an elevated customer and product experience is a critical success factor. Our unrivalled commitment to rolling out a differentiated sales strategy will allow us to generate significant revenues in this rapidly growing market."  

Prior to joining Bonify, Bains founded and drove the growth of Amenity Health Care, an independent pharmacy group that in four short years became one of the largest independent pharmacy groups in Canada. In 2017, Bains and a team of investors sold the group to private equity firm, TorQuest Partners.

Key facts:

About Bonify

Bonify is a Canadian-owned Licensed Producer and leading provider of medical cannabis. By maximizing research findings and strictly adhering to best-in-class practices, quality standards and procedures, Bonify produces medical cannabis products to help individuals get the most out of life each and every day. With over 1,000,000 square feet of potential productive capacity at its present site in Winnipeg, Manitoba, Canada, when at full scale, Bonify will be capable of growing over 100,000 kg of cannabis annually. For more information, visit www.bonify.com.

SOURCE Bonify


These press releases may also interest you

at 01:35
Regulatory News: Pernod Ricard (Paris:RI): Press Release ? Paris, 25 April 2024 This robust performance illustrates the strength of our diversified portfolio of premium international spirits and our broad-based geographic footprint covering...

at 01:30
Happiest Minds Technologies Limited (NSE: HAPPSTMNDS), a 'Born Digital. Born Agile', Mindful IT Company, today announced it signed definitive agreements to acquire 100% of the equity share capital of PureSoftware Technologies Private Limited...

at 01:21
Aker Solutions has delivered strong revenue growth and improved profitability in the first quarter of 2024 compared to the same period last year. With a solid backlog and high tendering activity, the company is well positioned for future profitable...

at 01:18
First Quarter Highlights            HMH delivered an EBITDA (adj.) of USD 33 million in quarter, about 75% increase year-over-year driven by higher aftermarket activityNES Fircroft delivered 17% increase in EBITDA and 12% revenue growth...

at 01:17
Quarter 1, 2024 - High profitability and strong cash flow Net sales decreased 4.1% to SEK 34,850m (36,352)Organic growth amounted to -4.0%, of which volume accounted for -1.8% and price/mix -2.2%. Excluding restructuring and exited contracts, volumes...

at 01:16
PERIOD 1 JANUARY - 31 MARCH 2024 Net sales decreased by 7% (same in local currencies) and amounted to SEK 1,995.2 (2,135.5) million. Acquired business contributed 1%.Operating result amounted to SEK 185.5 (313.5) million.Result for the period...



News published on and distributed by: